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ABSTRACT
Epigenetic dysregulation is one of many factors that contribute to cancer 
development and progression. Numerous epigenetic alterations have been identified 
in urologic cancers including histone modifications, DNA methylation changes, 
and microRNA expression. Since these changes are reversible, efforts are being 
made to develop epigenetic drugs that restore the normal epigenetic patterns of 
cells, and many clinical trials are already underway to test their clinical potential. 
In this review we analyze multiple clinical trials (n=51) that test the efficacy of 
these drugs in patients with urologic cancers. The most frequently used epigenetic 
drugs were histone deacetylase inhibitors followed by antisense oligonucleotides, 
DNA methyltransferase inhibitors and histone demethylase inhibitors, the last of 
which are only being tested in prostate cancer. In more than 50% of the clinical 
trials considered, epigenetic drugs were used as part of combination therapy, which 
achieved the best results. The epigenetic regulation of some cancers is still matter 
of research but will undoubtedly open a window to new therapeutic approaches in 
the era of personalized medicine. The future of therapy for urological malignancies 
is likely to include multidrug regimens in which epigenetic modifying drugs will play 
an important role.
INTRODUCTION
Urologic cancers account for approximately 10% of 
all cancer deaths in the USA and include bladder, kidney, 
prostate and testicular cancers [1]. 
The establishment and progression of malignancy 
involves broad changes in gene expression that are 
determined by both genetic and epigenetic events. 
Genetic events include chromosome rearrangements 
and duplications as well as translocations, deletions, and 
single base pair mutations. Epigenetic modifications are 
somatically heritable changes that modify gene expression 
without altering the DNA sequence. Among these are 
histone modifications, DNA methylation, and miRNA 
expression [2]. 
HISTONE MODIFICATIONS
Post-translational modification of the histone protein 
N terminal tails can alter the structure of the nucleosome 
and change the compaction state of chromatin. Common 
modifications include methylation, acetylation, 
phosphorylation, ubiquitylation and sumoylation [2]. 
Among these, histone acetylation and methylation are best 
described in cancer epigenetic dysregulation [2].
Histone acetylation neutralizes the positive charge of 
lysine residues, weakening their electrostatic interactions 
with DNA [3]. This leads to a more relaxed state of the 
chromatin and is associated with transcriptional activation. 
Addition of the acetyl group is carried out by histone 
acetyltransferases (HATs), and its removal is catalyzed by 
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histone deacetylases (HDACs) [4]. HDACs are classified 
into four distinct groups based on their homology to yeast 
histone deacetylases. Class I HDACs encompass HDAC1, 
2, 3 and 8 and, with the exception of HDAC8 that can 
be located in the nucleus or cytoplasm, are exclusively 
located in the nucleus. Class II HDACs include HDAC4, 
5, 6, 7, 9 and 10 and can be present in the nucleus or 
the cytoplasm [5, 6]. Class III HDACs are the sirtuins, 
proteins which require the cofactor NAD+ to be active. 
Unlike Class I and Class II HDACs, sirtuins are not 
inhibited by known pharmacologic HDAC inhibitors 
(HDACi) such as Vorinostat and Trichostatin A (TSA) [5, 
6].
Histone methylation occurs at lysine and 
arginine residues and, depending on the target, can 
lead to activation or repression of gene expression [7]. 
Methylation is catalyzed by histone methyltransferases 
(HTMs) while demethylation is performed by histone 
demethylases (HDMs). There are currently two histone 
demethylase families, the lysine specific demethylases 
(LSD) and the JmjC-domain-containing histone 
demethylases (JHDMs) [7]. The LSDs comprise LSD1 
and LSD2, which are dependent on FAD to be catalytically 
active [8]. The JHDMs in turn, catalyze the hydroxylation 
of the lysine methylgroup and require two factors to be 
catalytically active: Fe(II) and 2-oxoglutarate [7].
In cancer, histone modifications have been 
associated with both activation and repression of gene 
expression. Modifications such as histone 3 methylation 
at lysine 4 (H3K4me), histone 3 di-methylation at lysine 
4 (H3K4me2), histone 3 tri-methylation at lysine 4 
(H3K4me3), histone 3 acetylation at lysine 9 (H3K9ac), 
histone 3 methylation at lysine 9 (H3K9me) and histone 
3 acetylation at lysine 27 (H3K27ac) are associated with 
active chromatin whereas histone 3 tri-methylation at 
lysine 36 (H3K36me3), histone 3 tri-methylation at lysine 
9 (H3K9me3) and histone 3 methylation at lysine 27 
(H3K27me) are associated with repressive chromatin [9].
DNA METHYLATION
DNA methylation results from addition of a 
methyl group to the 5-carbon of a cytosine residue by the 
enzyme DNA methyltransferase (DNMT) [10]. DNMT 
forms a complex with CpG dinucleotides that allows the 
transfer of a methyl group to the cytosine residue [10]. 
Many CpG sites are located in the promoter regions of 
genes. Collectively they are known as CpG islands. 
In general, DNA methylation of CpG islands located 
in gene promoters leads to transcriptional repression. 
However, there are exceptions to this classical view, in 
which promoter hypermethylation is associated with 
increased gene expression [11-14]. This occurs in 
instances where DNA methylation drives the use of an 
alternative transcription start site or inhibits the binding of 
a repressive protein [15]. Increased gene expression in the 
context of promoter hypermethylation is associated with 
an increase in H3K4me3, a histone mark characteristic of 
gene activation [15].
In eukaryotes, DNA methylation is mediated by 
three DNMTs: DNMT1 is responsible for the maintenance 
of methylation patterns after DNA replication whereas 
DNMT3A and DNMT3B carry out de novo methylation 
[4]. Any alteration that affects the activity of these 
enzymes can lead to an imbalance in methylation that 
provides the basis, or contributes, to the initiation of 
carcinogenesis. 
MIRNAS 
miRNAs are small endogenous non-coding RNAs 
(ncRNAs), 21-25 nucleotides in length, that regulate 
gene expression by targeting specific messenger RNAs 
(mRNAs) for translational repression or degradation. 
Expression patterns of miRNAs differ between normal 
and tumor tissues [16, 17]. Depending on their target, 
miRNAs can act either as tumor suppressors or oncogenes; 
downregulation of an miRNA that targets an oncogene, 
or an overexpression of an miRNA that targets a tumor 
suppressor gene, can promote carcinogenesis [16, 17]. 
EPIGENETIC DRUGS 
Two strategies for epigenetic therapy are currently 
in use: small molecules that inhibit epigenetic-modifying 
enzymes and manipulation of miRNA expression. 
Amongst the small molecule inhibitors are HDAC 
inhibitors and DNMT inhibitors. HDAC inhibitors 
(HDACi) are classified into 4 groups according to their 
chemical structures: hydroxamates (SB393, Vorinostat, 
Panobinostat), cyclic peptides (Romidepsin), benzamides 
(Entinostat and Mocetinostat) and aliphatic fatty acids 
(Valproic Acid) [18]. 
The majority of HDACi inhibit zinc-dependent 
HDACs by interacting with the zinc ion. In cancer cells, 
the inhibition of histone deacetylation restores expression 
of tumor suppressor genes that were previously silenced 
by epigenetic mechanisms [18, 19]. 
DNMT inhibitors are divided into nucleoside 
analogues and non-nucleoside analogs [4]. Nucleoside 
analogues, such as Azacitidine, Decitabine and FdCyd, 
are cytosine analogs modified at the C5 position. Inside 
the cell they are metabolized and incorporated into DNA 
molecules [4]. DNA methyltransferases can bind to these 
modified nucleotides but their modification at C5 prevents 
their methylation. It also prevents the dissociation of the 
enzyme thereby reducing DNMT activity at other sites 
[4]. Non-nucleoside analogues, such as Hydralazine, 
Procainamide and MG98, inhibit methylation by binding 
to the catalytic region of the enzyme [4]. 
Another focus of epigenetic therapy is the 
manipulation of miRNA expression and activity. Several 
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strategies have been employed to silence miRNAs that 
are overexpressed in cancer. These include anti-miRNA 
oligonucleotides (AMOs), peptide nucleic acids (PNAS), 
miRNA-masking antisense oligonucleotides (miR-
mask) and miRNA sponges [16]. Restoration of miRNA 
expression that has been downregulated in cancer is 
Figure 1: Epigenetic therapies in clinical trials for prostate, bladder and kidney cancers. A. Percentage of clinical trials 
employing each types of epigenetic therapeutic agents in prostate cancer; B. Percentage of clinical trials using mono or combined therapy 
as therapeutic strategy with the different classes of epigenetic drugs in prostate cancer; C. Percentage of clinical trials where different 
agents are used in combined therapies for prostate cancer; D. Percentage of clinical trials employing each types of epigenetic therapeutic 
agents in kidney cancer; E. Percentage of clinical trials using mono or combined therapy as therapeutic strategy with the different classes of 
epigenetic drugs in kidney cancer; F. Percentage of clinical trials where different agents are used in combined therapies for kidney cancer G. 
Percentage of clinical trials employing each types of epigenetic therapeutic agents in bladder cancer; H. Percentage of clinical trials using 
mono or combined therapy as therapeutic strategy with the different classes of epigenetic drugs in bladder cancer; I. Percentage of clinical 
trials where different agents are used in combined therapies for bladder cancer
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achieved by administration of synthetic miRNAs or by 
induced expression of miRNA coding genes using viral 
constructs, such as adenovirus-associated vectors [16].
Dysregulation of epigenetic marks leads to 
changes in gene expression that, in cancer cells, can 
result in activation of oncogenes or inactivation of tumor 
suppressor genes, both of which can contribute to cancer. 
Unlike genetic mutations, however, epigenetic changes are 
reversible. Therefore, the development of drugs capable of 
restoring the normal epigenetic patterns of cells has great 
therapeutic potential. In this review we discuss the efficacy 
of this novel therapeutic approach through the analysis of 
clinical trials of epigenetic therapies conducted in prostate, 
kidney and bladder cancers. 
METHODS
We performed a comprehensive literature review 
and searched for clinical trials from the United States 
(https://clinicaltrials.gov/) and European (https://www.
clinicaltrialsregister.eu/) databases. Relevant articles on 
the subject were also retrieved from PubMed database 
using keywords encapsulating all types of epigenetic 
therapies and urologic cancers (examples: “epigenetic 
therapy” AND “urologic cancer”, “prostate cancer” 
AND “HDACi”, “kidney cancer” AND “DNMTi”). 
To guarantee that most of the data on the subject was 
included, the reference sections of the captured articles 
were also filtered for relevant articles. 
Prostate cancer - epigenetics
Dysregulation of epigenetic-modifying enzymes 
disturbs normal epigenetic patterns and is associated 
with cancer development and progression. In prostate 
cancer, DNA methyltransferases are upregulated [20, 
21]. Histone-modifying enzymes, such as HDACs are 
upregulated in prostate cancer [22]. HMTs and HDMs 
show variable changes in expression with a tendency for 
upregulation of HMTs and lower expression of HDMs 
[23, 24]. Prognostically, overexpression of HDAC2 is 
associated with a shortened time before prostate cancer 
recurrence as shown in a subgroup of patients with 
Gleason Score 7 carcinomas, [6]. 
Specific histone modifications have also been 
associated with prostate cancer [25, 26]. The levels of 
histone marks H3Ac and H3K9me2 are significantly 
lower in tumor tissue when compared to normal tissue 
[26]. Conversely, an increase in H3K27me3 is found in 
metastatic tissue relative to localized tumors and normal 
prostatic tissue [25]. Finally, higher levels of H3K4me1 
are associated with a higher probability of recurrence [26].
Changes in DNA methylation are also evident in 
prostate cancer and are targets for epigenetic therapy. The 
CCDN2, GSTP1 and RARβ2 genes, involved in cell cycle 
control, DNA repair mechanisms and hormonal responses 
respectively, are hypermethylated in prostate cancer. 
Alteration of their normal methylation status is correlated 
with poor clinical prognosis [26]. As with many epigenetic 
alterations, these biomarkers are useful in diagnosis and 
prognosis of disease [25, 26]. 
Finally, miRNA levels are also altered in prostate 
cancer, affecting the expression of genes involved in cell 
cycle control, apoptosis, migration, and invasion [27]. 
Levels of miRNAs also have the potential to be used 
as biomarkers for diagnosis and prognosis [25]. As an 
example, miR-141 is upregulated in prostate cancer [25, 
28]. Serum levels of this miRNA can distinguish between 
tumor and healthy tissue and higher levels of miR-141 
are associated with worse prognosis [28]. miR-449a is 
another miRNA that is downregulated in prostate cancer. 
It targets HDAC1, so its downregulation contributes to 
overexpression of this enzyme, showing that epigenetic-
modifying enzymes are often regulated epigenetically [27, 
29].
Prostate cancer - current treatment 
Prostate cancer treatment is disease stage-specific. 
Epigenetic therapies have thus far been limited to the 
advanced form of castrate resistant prostate cancer 
(CRPC). Currently there are several chemotherapeutic 
agents approved for the treatment of advanced CRPC: 
Sipuleucel T, Docetaxel, Cabazitaxel, Abiraterone, 
Alpharadin and Enzalutamide [30-35]. Although all 
of these agents have shown efficacy, strategies for the 
sequence of administration and their combination are 
still being optimized [36]. Treatment resistance is a major 
concern with some of these agents, including Abiraterone 
and Enzalutamide, reflecting the need for ongoing 
development of novel therapeutic strategies [36]. Since 
epigenetic dysregulation contributes to the development 
of treatment resistance, epigenetic therapy is an intriguing 
addition to the CRPC therapy arsenal [37].
Prostate cancer - pre-clinical data
Pre-clinical studies in prostate cancer cell lines 
demonstrate that treatment with HDACi can restore 
susceptibility to chemotherapeutic agents such as taxanes, 
antiandrogens, and mTOR inhibitors [38-40]. Combined 
therapy using HDACi and taxanes prevents tumor 
growth and increases cell death rate when compared to 
a monotherapeutic approach [38]. Liu et al showed that 
low doses of the HDACi Panobinostat can restore the 
susceptibility of prostate cancer cells to hormonal therapy 
with the nonsteroidal antiandrogen Bicalutamide [39]. 
The HDACi Belinostat (PXD101) can also downregulate 
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Table 1: Clinical trials of epigenetic drugs in prostate cancer
Drug Combined Therapy Enzimatic Class Approval Stage Status Indication Results Reference/Clinical trial identification 
SB939 - HDAC inhibitor Phase 2 Completed Castration Resistance Prostate Cancer (CRPC)
6% of the patients 
had a PSA response 
64% of the patients had 
a conversion from an 
unfavorable CTC profile 
to a favorable one
Eigl et al. 2015
(NCT01075308)
Panobinostat - HDAC inhibitor Phase 2 Completed CRPC
14,3% of the patients had 
a PSA decrease <50% but 
no objective responses 
were seen
11,4% of the patients had 
stable disease for at least 
24 weeks
Rathkopf et al. 2013
(NCT00667862)
Panobinostat Docetaxel HDAC inhibitor Phase 1 Completed CRPC 63% had a PSA decrease >= 50% Rathkopf et al. 2010
Panobinostat Radiotherapy HDAC inhibitor Phase 1 Completed
Prostate Cancer, 
esophageal cancer and 
neck cancer
No study results or 
publications provided NCT00670553
Panobinostat Docetaxel/prednisone HDAC inhibitor Phase 2 Completed CRPC No study results or publications provided NCT00878436
Panobinostat Bicalutamide HDAC inhibitor Phase 1 Completed CRPC No study results or publications provided NCT00663832
Vorinostat - HDAC inhibitor Phase 2 Completed Progressive metastatic prostate cancer
No PSA declines >=50% 
were observed
Median of progression 
free survival=2,8 months 
with a median overall 
survival of 11,7 months
Bradley et al. 2010
(NCT00330161)
Vorinostat
 
 
Docetaxel HDAC inhibitor Phase 1 Terminated 
Advanced solid tumor 
including prostate cancer, 
urothelial carcinoma and 
kidney cancer
This study was 
terminated due to 
excessive toxicity as 
five patients experienced 
dose-limiting toxicities 
(DLT)
 
No responses were 
observed
Schneider et al. 2012
(NCT00565227)
Vorinostat Temsirolimus HDAC inhibitor Phase 1 Terminated Metastatic prostate cancer
This study was 
terminated due to lack of 
efficacy
NCT01174199
Vorinostat Androgen deprivation therapy HDAC inhibitor Phase 2 Completed Localized prostate cancer
No study results or 
publications provided NCT00589472
Vorinostat - HDAC inhibitor Phase 1 Completed Advanced solid tumors including prostate cancer
No study results or 
publications provided NCT00005634
Romidepsin - HDAC inhibitor Phase 2 Completed Metastatic prostate cancer
No study results or 
publications provided NCT00106418
Romidepsin - HDAC inhibitor Phase 2 Completed
metastatic castration-
resistant prostate cancer 
(MCRPC)
63% of the patients 
had progressive disease 
with a median time to 
progression of 49,5 days 
PSA decline >=50% was 
observed in 5,7% of the 
patients 
Molife et al. 2009
 
Curcumin Docetaxel HDAC inhibitor Phase 2 Ongoing MCRPC
Final data collection date 
for primary outcome 
measure: January 2017
NCT02095717
Curcumin - HDAC inhibitor Phase 2 Ongoing Prostate cancer
Estimated primary 
completion date: June 
2020
NCT02064673
Curcumin Radiotherapy HDAC inhibitor - Completed Prostate cancer
No PSA response was 
observed but the severity 
of radiotherapy related 
urinary symptoms was 
reduced, 
Hejazi J. et al. 2013
Dissulfiram - DNMT inhibitor Phase 1 Completed Non-metastatic recurrent prostate cancer
Five patients achieve a 
transient demethylation 
response 
Six patients discontinue 
therapy due to adverse 
effects
Schweizer et al. 2013
Azacitidine Combined Androgen Blockade (CAB) DNMT inhibitor Phase 2 Completed CRPC
Overall median PSA 
doubling time increased 
significantly (2.8 vs 1.5 
months of the baseline). 
Median of progression 
free survival=12,4 weeks 
Fourteen patients had 
some PSA decline and 1 
patient had a PSA decline 
>=30%
Sonpavde et al. 2011
Azacitidine - DNMT inhibitor Phase 2 Completed Prostate cancer No study results or publications provided NCT00384839
Azacitidine Docetaxel/prednisone DNMT inhibitor Phase1/2 Terminated CRPC
This study was 
terminated due to 
withdrawal of funding
Complete and partial 
response were achieved 
by one and two patients, 
respectively 
NCT00503984
Phenelzine sulfate - HDM inhibitor/monoamine oxidase A inhibitor Phase 2 Ongoing
Non-metastatic recurrent 
prostate cancer
Study completion date: 
August 2018 NCT02217709
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the androgen receptor, preventing the onset of castration 
resistant prostate cancer in vivo in the context of hormonal 
therapy [41]. 
An in vitro study of the HDACi Panobinostat in 
combination with the mTOR inhibitor Rapamycin in 
prostate cancer cell lines resulted in a decrease in HIF1- 
α expression leading to inhibition of angiogenesis [40]. 
Combined therapy with these agents was more efficient 
than either one administrated alone [40].
Cancer stem cells are thought to be responsible for 
treatment resistance and tumor recurrence [42] and present 
epigenetic alterations that contribute to their ability to 
resist therapy [42]. Epigenetic therapeutics may therefore 
have the potential to target not only the bulk tumor but 
also this key subset of cells [42]. A study carried out 
by Frame et al revealed that prostate stem-like cells are 
more resistant to radiotherapy [43]. However, combined 
therapy with HDACi restored sensibility to radiotherapy 
[43]. Additionally, prostate stem-like cells treated jointly 
with the HDACi Trichostatin A and radiotherapy showed a 
significant reduction in the number of cell colonies formed 
when compared to treatment with radiation alone [43]. 
Cancer is a heterogeneous disease and the 
identification of biomarkers that predict whether a 
specific therapy (including epigenetic therapies) will be 
beneficial, is essential to improving cancer treatment. 
Recently, it has been reported that prostate cells positive 
for the presence of androgen receptor and cellular prostatic 
acid phosphatase show greater response to treatment with 
HDACi than cells without this pattern of expression [44]. 
At the level of DNA methylation, reversion of 
methylation can restore expression of genes silenced by 
this epigenetic mechanism. Treatment of human prostate 
cancer cells with Procainamide, a non-nucleoside DNMT 
inhibitor, results in a decrease in GSTP1 methylation levels 
and a consequent increase in gene expression [45]. In vivo, 
treatment of immunodeficient mice carrying xenograft 
tumors with Procainamide resulted in a significant 
reduction in tumor size, suggesting clinical efficacy [45]. 
Resistance to hormonal therapy in prostate 
cancer is mediated by several mechanisms. Alterations 
at the DNA level include androgen receptor gene 
amplifications and point mutations [46]. However, these 
modifications account for only a minority of cases. 
Phenelzine sulfate Docetaxel HDM inhibitor/monoamine oxidase A inhibitor Phase 2 Ongoing
Progressive prostate 
cancer
Final data collection date 
for primary outcome 
measure: January 2016
NCT01253642
OGX-011
 
 
 
Docetaxel/
prednisone
Antisense oligonucleotide 
that targets clusterin Phase 1
Completed
 
advanced cancer 
including prostate, 
bladder and kidney 
cancer
Six patients with 
hormone-refractory 
prostate cancer had a PSA 
decline >=50%
 
Saad et al. 2011 (NCT00471432)
OGX-011
Docetaxel/
prednisone 
and docetaxel/
mitoxantrone
Antisense oligonucleotide 
that targets clusterin Phase 3 Completed MCRPC
No objective responses 
were seen
41% of the patients 
discontinued treatment 
due to serious adverse 
events
Chi et al. 2008
(NCT01188187)
OGX-011 Cabazitaxel/prednisone
Antisense oligonucleotide 
that targets clusterin Phase 3 Ongoing CRPC
Study completion date: 
December 2016 NCT01578655
Oblimersen Docetaxel Antisense oligonucleotide that targets Bcl-2 Phase 2 Completed CRPC
PSA response was 
observed in 46% and 37% 
of the patients treated 
with docetaxel alone and 
docetaxel+oblimersen, 
respectively 
 
Partial response was 
observed in 18% and 
24% of the patients in 
the referred groups and 
major toxic events were 
reported in 22,8% and 
40,7% respectively
Sternberq et al. 2009 (NCT00085228)
Oblimersen sodium 
(Genasense) Mitoxantrone
Antisense oligonucleotide 
that targets Bcl-2 Phase 1 Completed CRPC
Two patients had a 
PSA reduction >=50%, 
1 patient had a PSA 
resuction <50%,  and 5 
patients had stable disease
Chi et al. 2001
OGX-427 Prednisone
Antisense oligonucleotide 
that targets heat shock 
protein27
Phase 2 Completed CRPC No study results or publications provided NCT01120470
OGX-427 Abiraterone
Antisense oligonucleotide 
that targets heat shock 
protein27
Phase 2 Ongoing MCRPC Study completion date: December 2017 NCT01681433
ISIS 1837 Docetaxel/prednisone
Antisense oligonucleotide 
that targets eIF4E Phase 2 Completed
Metastatic resistant 
castrate prostate cancer
No study results or 
publications provided EudraCT Number: 2010-022239-12
ISIS 3521/ISIS 
5132 -
Antisense oligonucleotides 
that targets PKC-α and 
Raf-1, respectively
Phase 2 Completed CRPC
No objective responses 
were observed but three 
patients had stable disease 
for 5 or more months
PSA values of five 
patients did not rise more 
than 25% for >=120 days
Tolcher et al. 2002
LY2181308 Docetaxel/prednisone
Antisense oligonucleotide 
that targets survivin Phase 2 Completed CRPC
No differences in efficacy 
were observed between 
the control and the 
experimental group. 
Higher incidence of 
adverse effects in the 
LY2181308 treated group.
Wiechno et al. 2014
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Downstream activation of the androgen receptor pathway 
and activation of an alternative signaling pathway can 
also contribute to hormonal therapy resistance [46]. 
Hypermethylation of the androgen receptor promoter 
region correlates with decreased androgen receptor 
expression and is also associated with the development 
of hormonal therapy resistance [47]. In vivo studies reveal 
that long-term treatment of prostate cancer cells with 
the DNMTi Azacitidine led to a significant reduction 
in cell proliferation due to increased androgen receptor 
expression. Moreover, androgen receptor induction 
restored sensitivity to the antiandrogen agent Bicalutamide 
[47]. 
The DNA demethylating agent, Disulfiram, has 
also been tested in prostate cancer cells. Treatment with 
Disulfiram resulted in the reestablishment of APC and 
RARβ gene expression, both of which are known to be 
hypermethylated and inactive in prostate cancer [48]. Cell 
growth inhibition was observed in vitro, and in vivo using 
prostate cancer xenograft models [48].
Finally, microRNAs modulators have been tested 
in preclinical studies as potential therapeutic options for 
prostate cancer. miR-16 regulates the expression of genes 
involved in cell-cycle control and apoptosis such as CDK1, 
CDK2 and BCL2 [49, 50]. Transfection of a synthetic 
miR-16 reduced the proliferative capacity of several 
prostate cancer cell lines [49]. In vivo, Takeshita et al 
used the atelocollagen method to deliver miR-16 to bone 
metastases via the mouse tail vein. They subsequently 
observed a suppression in metastasis growth, indicating 
not only efficacy of the treatment but also of the delivery 
method [49].
Like HDACi and DNMTi, antisense 
oligonucleotides can restore the sensitivity of cancer cells 
to chemotherapeutic agents. Upregulation of the Bcl2 and 
CLU genes in prostate cancer is linked to chemoresistance 
and cancer progression [51, 52]. Knockdown of these 
genes by antisense oligonucleotides decreases gene 
expression and reestablishes tumor sensitivity to taxane-
based chemotherapy [51, 52]. Furthermore, transfection 
of miR-449a into prostate cancer cells lines caused cell 
cycle arrest and a decrease in HDAC1 levels, an effect 
also observed after knockdown of HDAC1 using an siRNA 
[29]. The inhibitory effect of miR-449a on cell cycle 
progression was associated with increased expression of 
the protein p27 [29]. 
These results demonstrate the potential for 
epigenetic therapies to advance prostate cancer treatment. 
Prostate cancer - clinical data
Clinical trials using HDAC inhibitors for the 
treatment of prostate cancer showed a PSA response in 
five studies, three of which resulted in a decrease in PSA 
levels of ≥50% (Table 1: NCT01075308, NCT00667862, 
NCT00330161, NCT00106418, [53-57]). The best 
results were obtain with the administration of the HDACi 
Panobinostat (Table1: NCT00667862, [54, 55]. Stable 
disease was reported in two clinical trials, but in one of 
them conversion from an unfavorable circulating tumor 
cell profile to a favorable one was observed in 64% of 
the patients (Table 1: NCT01075308, NCT00667862, 
NCT00330161, [53, 54, 56]).
Most common side effects were grade 2 fatigue and 
nausea. In addition, HDACi SB939 caused five patients to 
experience one or more grade 3 complications (Table 1: 
NCT01075308, [53]). More severe side effects were noted 
with HDACi Panobinostat, resulting in 71, 4% of the 
patients experiencing one or more grade 3 adverse effects 
and four subjects reporting grade 4 adverse effects (Table1: 
NCT00667862, [54]). Another trial using Panobinostat 
reported no grade 4 toxicities when administered as 
monotherapy [55], however, when administered in 
combination with Docetaxel, seven patients experienced 
grade 4 toxicities [55] (Table 1). HDACi Vorinostat also 
showed a complex side effect profile. When administered 
alone in patients pre-treated with chemotherapeutic agents 
it led to the development of grade 3/4 toxicities in 48% of 
the patients, with 41% of the patients forced to discontinue 
therapy due to their severity (Table 1: NCT00330161, 
[56]). A second trial of Vorinostat in combination with 
docetaxel was terminated early due to excessive toxicity 
as five patients experienced dose-limiting toxicities, 
including two patients experiencing neutropenic fever and 
sepsis. The other three patients reported an anaphylactic 
reaction, a myocardial infarction and a gastrointestinal 
bleed, respectively (Table 1: NCT00565227, [58]). Finally, 
a trial of the HDACi Romidepsin in metastatic prostate 
cancer resulted in no grade 4 toxicities, and grade 3 events 
represented only 4.7% of all reported adverse effects 
(Table 1: NCT00106418, [57]).
Curcumin, a compound found in the spice 
turmeric, is another HDACi [59]. A trial of Curcumin in 
prostate cancer showed no PSA response when used in 
combination with radiotherapy (Table 1: NCT01917890, 
[60]). However, there was a significant reduction in 
urinary symptoms, one of the most common side effects 
of radiotherapy (Table 1: NCT01917890, [60]). Two 
additional trials testing Curcumin in the treatment of 
prostate cancer are ongoing (Table 1: NCT02095717, 
NCT02064673). 
DNMT inhibitors have also showed promising 
results in clinical trials of prostate cancer. When treated 
with the DNMTi disulfiram, five patients achieved a 
transient demethylation response. No grade 4 adverse 
effects were observed in this trial but 6 patients were 
forced to quit due to treatment toxicity (Table 1: 
NCT01118741, [61]). The DNMTi Azacitidine was trialed 
in chemonaive patients with CRPC in combination with 
combined androgen blockade (CAB). PSA doubling time 
increased relative to patients receiving only CAB and no 
grade 4 toxicities were reported, although 4 patients had to 
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stop treatment due to grade 3 toxicities [62]. 
Azacitidine has also been tested in combination 
with Docetaxel and Prednisone in CRPC (Table 1: 
NCT00503984). Therapeutic response was assessed by 
magnetic resonance imaging with a complete response 
considered the disappearance of target lesions, and a 
partial response considered a ≥30% decrease in the sum 
of the longest diameter of targeted lesions. Complete 
and partial responses were achieved by only one and 
two patients, respectively. A PSA response was observed 
in 10 patients. Despite some positive results, the study 
was terminated due to withdrawal of funding (Table 1: 
NCT00503984). More studies are needed to assess the 
clinical potential of this agent.
Another category of epigenetic drugs with clinical 
potential in cancer treatment are HDM inhibitors. 
Phenelzine is a monoamine oxidase A (MAOA) 
inhibitor used in the treatment of psychiatric disease. 
MAOA is an enzyme responsible for the deamination 
of neurotransmitters, such as dopamine, serotonin 
and norepinephrine, that are important in a variety of 
neurological and psychiatric illnesses [63]. MAOA has 
close homology to LSD1, a histone demethylase, which 
catalyzes removal of the methyl group from H3K4me1 
and H3K4me2. As a result of this homology, Phenelzine 
is able to bind and inhibit LSD1. [63]. Lower levels of 
H3K4me2 are correlated with higher risk of recurrence in 
prostate cancer [64]. Phenelzine is currently being trialed 
as a monotherapy for the treatment of recurrent prostate 
cancer and in combination with docetaxel for the treatment 
of progressive prostate cancer. Given that Phenelzine is 
already an approved medication, positive responses in 
these clinical trials will open the door to using this class 
of epigenetic drugs in clinical practice in the near future. 
In the area of miRNA modulation, four clinical 
trials of antisense oligonucleotides have reported a 
positive PSA response, with three trials describing a PSA 
response >=50% (Table 1: NCT01188187, NCT00471432, 
NCT00085228, [65-68]). One of these trials, evaluating 
the efficacy of the antisense oligonucleotide OGX-011 in 
combination with docetaxel or mitoxantrone, reported a 
PSA decrease ≥50% in 6 of 14 patients with CRPC (Table 
1: NCT00471432, [66]). Most of the adverse effects were 
grade 1 and 2 only, however adverse effects of grade 3 
or higher affected 60% of the patients receiving the 
antisense oligonucleotide in combination with docetaxel/
prednisone and 73% of the patients receiving the OGX-
011 in combination with mitoxantrone/prednisone (Table 
1: NCT00471432, [66]). The most common grade 3 or 
higher adverse effects in both groups were fatigue and 
lymphopenia (Table 1: NCT00471432, [66]). OGX-
011 was also tested in combination with docetaxel and 
prednisone in a phase III clinical trial but, despite some 
positive results observed in phase II of the study where 
58% of the patients had a PSA response >=50%, no 
significant results were observed in phase III (Table 1: 
NCT00471432, NCT01188187, [66, 69]). In the group 
receiving the combined therapy OGX-011/docetaxel/
prednisone, 41% of the patients had to discontinue the 
treatment program due to adverse effects of the therapy 
(≥3 grade) (Table 1: NCT01188187, [69]).
Administration of the antisense oligonucleotide 
LY2181308 to decrease the expression of survivin, an 
anti-apoptotic gene involved in therapy resistance was 
tested in a randomized phase 2 clinical trial performed by 
Wiecho et al for the treatment of CRPC [70]. The patients 
allocated in the group treated with LY2181308 reported 
higher incidence of grade 3 and 4 adverse effects without 
any improvement in progression free survival or overall 
survival of the patients [70].
Disappointing results were obtained with another 
antisense oligonucleotide, Oblimersen, that was trailed 
by Sternberg et al both alone and in combination with 
docetaxel (Table 1: NCT00085228, [67]). The authors 
observed a PSA response in 46% of the patients treated 
with docetaxel alone, versus 37% of the patients treated 
with the antisense oligonucleotide and docetaxel (Table 1: 
NCT00085228, [67]). In the group of patients receiving 
the combined therapy, major toxic events were observed 
in 40.7% of the patients, compared to 22.8% of the 
patients receiving the antisense oligonucleotide alone, 
indicating that docetaxel increased oblimersen-related 
toxicity. This suggests that combined therapy with 
antisense oligonucleotides and taxanes might not the best 
therapeutic approach (Table 1: NCT00085228, [67]). In 
another clinical trial Oblimersen was administrated in 
combination with mitoxantrone, with 2 patients out of 25 
showing a PSA decrease equal or superior to 50%. One 
patient had a PSA response inferior to 50% while stable 
disease was observed in a further five patients [68]. 
Although no clinical benefits were observed in a 
study testing the antisense oligonucleotides ISIS 3512 and 
ISIS 5132, two patients who received the oligonucleotide 
ISIS 3512 and one patient who received ISIS 5132 did 
not show disease progression for at least five months 
[71]. Finally, results are currently unavailable from eight 
completed clinical trials and two other trials are ongoing 
(Table 1).
Kidney cancer - epigenetics
Genetic and epigenetic dysregulation of genes 
involved in pathways such as the hypoxia-inducible 
pathway, the mTOR pathway, and the cMET-RAF-MEK-
ERK pathway contribute to the progression of kidney 
cancer [72]. Changes in the levels of epigenetic-modifying 
enzymes are an important factor in altering expression of 
genes involved in cancer-related pathways. In renal cell 
carcinoma (RCC), an increase in the levels of histone 
demethylases such as UTX, JMJD2 and EZH2, results 
in a reduction in H3K27me and promotes progression of 
the disease [73, 74]. Also in RCC, almost 60% of patients 
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overexpress HDAC1 and HDAC2 [75]. No prognostic 
value has been associated with these alterations [75]. 
HDAC3 is also highly expressed, but only in the papillary 
carcinoma subset [75]. 
At the level of individual epigenetic changes, 
low levels of H3K4me2, H3K18Ac, and H3K9me2 
are associated with poor prognosis and lower survival 
probability in RCC. , Mechanistically, H3K4me2 and 
H3K18Ac are associated with active transcription while 
H3K9me2 is associated with transcriptional repression 
[73, 74]. H3K27me is another histone modification 
that correlates with poor clinical outcome, result of 
overexpression of histone demethylases in RCC [73, 74]. 
Clear cell RCC is the most common form of renal 
cell carcinoma, and is associated with inactivation of the 
tumor suppressor gene von-Hippel Lindau (VHL) by either 
genetic and epigenetic factors [76, 77]. VHL inactivation 
in both sporadic and familial forms can occur due to point 
mutations or deletions at the genetic level, or due to DNA 
hypermethylation at the gene promoter [76, 77]. 
DNA methylation also affects the regulation of 
several genes in RCC and has the potential to be used as 
biomarker and as a therapeutic target [78]. For example, 
hypermethylation of RASSF1A and HIC in patients with 
RCC is associated with a poor prognosis [79, 80].
Several miRNAs showed altered expression in RCC, 
resulting in changes to important cellular functions such as 
apoptosis, angiogenesis and the epithelial mesenchymal 
transition [27, 81]. Examples of miRNAs with altered 
expression in RCC include miR-210, miR-34a, miR-30c, 
miR-29b and miR-23b [27, 81]. 
Kidney cancer - current treatment 
Radical nephrectomy is the standard of care for 
localized renal cell carcinoma. However, high rates of 
recurrence after surgery demand the development of 
new adjuvant therapies. Both radiotherapy and hormone 
therapy have proven ineffective in advanced stages of 
disease and chemotherapy has a response rate inferior to 
10% [82, 83]. 
Table 2: Clinical trials of epigenetic drugs in kidney cancer
Drug Combined Therapy Enzimatic Class Approval Stage Status Indication Results
Reference/Clinical 
trial identification
Vorinostat Bevacizumab HDAC inhibitor Phase 1/2 completed Unresectable or metastatic kidney cancer
48,6% of the patients had absence 
of disease progression at 6 months 
 
8,11% of the patients experienced 
serious adverse events
NCT00324870
Vorinostat Isotretinoin HDAC inhibitor Phase 1/2 Completed Advanced renal cell carcinoma
MTD of Vorinostat in combination 
with isotretinoin=0,5 mg/kg NCT00324740
Vorinostat - HDAC inhibitor Phase 2 Completed Advanced renal cell carcinoma
An objective response was 
observed in 36% of the patients 
63% of the patients demonstrate 
progressive disease and one patient 
had serious adverse events
NCT00278395
Vorinostat Pembrodizumab HDAC inhibitor Phase 1 Ongoing Advanced renal or urothelial cell carcinoma
Final data collection date for primary 
outcome measure: May 2018 NCT02619253
Panobinostat - HDAC inhibitor Phase 2 Completed Refractory clear cell renal carcinoma
Median of progression free 
survival=1,7 months
30% of the patients experienced 
serious adverse events
Hainsworth et al. 2011 
(NCT00550277)
 
Panobinostat Everolimus HDAC inhibitor Phase ½ Terminated Metastatic or unresectable renal cell cancer
The study has been terminated 
(patients off study, principal 
investigator left institute)
NCT01582009
Panobinostat Sorafenib HDAC inhibitor Phase 1 Ongoing Advanced renal cell carcinoma
Study completion date: November 
2016 NCT01005797
Entinostat Isotreitinoin HDAC inhibitor Phase 1 Completed
solid tumor including kidney 
cancer, urothelial carcinoma 
and prostate cancer
No objective responses were 
observed but stable disease was 
noticed in patients with kidney, 
prostate and pancreatic cancer 
 
Recommended doses for phase 2: 4 
mg/m of entinostat once weekly and 
1mg/kg of isotretinoin per day
Pili et al. 2012
Entinostat IL-2 HDAC inhibitor Phase 1/2 Ongoing Metastatic kidney cancer No date given for study completion NCT01038778
Decitabine Interferon alpha2B DNMT inhibitor Phase 2 Terminated Advanced renal cell carcinoma
The study was terminated due to low 
accrual and unavailable treatment 
agent. 
NCT00561912
Decitabine IL-2 DNMT inhibitor Phase 1 Completed Melanoma or renal cell cancer Three patients with renal cell cancer had stable disease Gollob et al. 2006
GTI-2040 Capecitabine
Antisense oligonucleotide 
that targets R2 subunit of 
ribonucleotide reductase
Phase 2 Completed Advanced/metatastic renal cell carcinoma
52% of the patients had stable disease 
with median duration of 4 months 
One partial response was observed
Desai et al. 2004
MG98 - Antisense oligonucleotide that targets DNMT1 Phase 2 Completed Metastatic renal carcinoma
Six patients had stable disease but no 
objective responses were seen Whinquist E. et al 2006
Oblimersen Interferon alpha Antisense oligonucleotide that targets bcl2 Phase 2 Completed Metastatic renal cell cancer
No study results or publications 
provided NCT00059813
MRX34  RNA mimic Phase 1 Terminated Renal cell carcinoma This study was terminated due to serious adverse events NCT01829971
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Kidney cancer - pre-clinical data
Preclinical studies using epigenetic drugs for kidney 
cancer treatment show some promise. In renal cancer cell 
lines, the HDACi Panobinostat induced cell cycle arrest 
and apoptosis and also resulted in a reduction in tumor 
size in xenograft mice models [84]. Pre-clinical studies 
of DNMT inhibitors in kidney cancer have also shown 
promise with evidence of reactivation of silenced genes 
and growth inhibition of cancer cells [85, 86]. 
One ongoing issue in RCC treatment is resistance 
to immunomodulatory therapy with interferons. This 
can occur via promoter hypermethylation and silencing 
of interferon response genes [87]. Treatment of renal 
cancer cell lines with 5-Aza-2’-deoxycitidine (5-Aza-dC), 
increased expression of interferon response genes and 
restored interferon induced apoptosis [87]. In addition, 
treatment of RCC cells with the antisense DNMT1 
oligonucleotide MG98 also restored susceptibility to 
interferon therapy [88].
Downregulation of miR-30c in RCC is associated 
with promotion of the epithelial mesenchymal transition 
[89]. Reduced expression of this miRNA is associated 
with hypoxia and VHL cell status with lower levels of 
miR-30c being observed in VHL-deficient RCC cell lines 
[89]. Transfection of a RNA mimic to restore miR-30c 
levels caused an increase in E-cadherin expression and 
reduced cell migration capacity [89]. 
Kidney cancer - clinical trials
Trials of HDACi in RCC have shown mixed 
responses. HDACi Vorinostat used as a monotherapy 
showed an objective response in 36% of patients, however 
63% of the patients presented disease progression at 
6 months (Table 2: s). When used in combination with 
Bevacizumab, 48, 6 % of the patients showed stable 
disease at 6 months (Table 2: NCT00324870). By 
contrast, treatment with Panobinostat alone resulted in 
no objective responses, and a median of progression-free 
survival of 1.7 months (Table 2: NCT00550277, [90]). 
Treatment was generally well tolerated, but 7 patients 
reported thrombocytopenia grade 3 or higher (Table 2: 
NCT00550277, [90]). In a separate small phase I trial, the 
HDACi Entinostat was administered in combination with 
Isotretinoin. One patient, who had presented with disease 
progression after treatment with cytokines and anti-
angiogenic therapy, subsequently showed stable disease 
[91]. The patient had a reduction in tumor size after 
4 months of therapy and did not show signs of disease 
progression at 12 months [91]. However, the number of 
patients enrolled in the study (2) was insufficient to draw 
any conclusions [91]. 
The only DNMT inhibitor tested in RCC is 
Decitabine. When used in combination with the cytokine 
IL-2 in a phase II study of advanced RCC, three out of 
five patients showed stable disease [92]. Another study 
combining Decitabine with interferon-α was terminated 
early due to low accrual (Table 1, NCT00561912). 
Treatment with antisense oligonucleotides has also 
resulted in stabilization of disease in some RCC patients. 
The antisense oligonucleotide GTI-2040, targeting the R2 
subunit of ribonucleotide reductase, was tested in patients 
with metastatic disease in a phase II trial and generated 
a partial response for approximately eight months [93]. 
One patient experienced a dose limiting toxicity (grade 3 
diarrhea) and adverse effects of all grades were reported 
in this trial including grade 4 pancytopenia, pulmonary 
embolism and bone pain [93]. In a trial reported by 
Winquist et al, in which the antisense oligonucleotide 
MG98 was administered to 15 patients, no objective 
responses were observed with nine patients presenting 
progression of the disease. MG98 targets DNMT1 but no 
decrease in enzyme activity was observed [94]. Also, grade 
3 and 4 adverse effects forced 8 patients to discontinue 
treatment, primarily due to elevations in alanine 
aminotransferase (ALT) and aspartate aminotransferase 
(AST) levels [94]. 
miRNA mimics have also been trialed in RCC. 
MRX34, an miRNA mimic of the tumor suppressor 
miRNA34, was tested in a phase I clinical trial for 
advanced or metastatic cancers, including RCC, but the 
trial was terminated early due to serious immunologic 
adverse events (Table 2: NCT01829971). 
Bladder cancer - epigenetics
Epigenetic modifications are important in bladder 
cancer development [95]. An increase in global histone 
methylation was reported in bladder cancer samples, 
particularly in the subset of patients with non-muscular 
invasive bladder cancer. In these patients, a global increase 
in H3K9 and H3K27 methylation was associated with 
high-grade tumors. However, the authors did not find 
any correlation between histone methylation and tumor 
recurrence or survival [96]. Interestingly, another study 
by the same group revealed that a decrease in methylation 
levels of other histone proteins, namely H3K4 and H3K20, 
could be a prognostic biomarker for muscle invasive 
bladder cancer [97]. The presence of different histone 
methylation patterns in muscle invasive and non-invasive 
bladder cancer, suggests that patients of these subgroups 
will respond differentially to epigenetic therapies affecting 
histone methylation. These data reinforce the need for 
biomarker discovery to predict responses to epigenetic 
therapy.
With respect to DNA methylation in bladder cancer, 
Friedrich et al reported hypermethylation of the genes 
DAPK, BCL2 and TERT in urine samples from patients 
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with bladder cancer [98]. Detection of methylation patterns 
in urine samples has proven to be a good diagnostic 
strategy in bladder cancer. [99, 100]. Methylation of 
some gene promoters can also be indicative of prognosis, 
for example, methylation of the RUNX3 promoter is 
associated with a higher risk of progression and lower 
survival [101].
Differential miRNA expression is another 
epigenetic feature of bladder cancer and can distinguish 
between cancer patients and healthy subjects [27, 102]. 
The miRNAs implicated in bladder cancer target genes 
involved in cell cycle control, cell proliferation, cell 
differentiation and signal transduction pathways [27, 
102]. Both upregulation and downregulation of miRNA 
expression can potentiate cancer development. In bladder 
cancer, loss of miR-200 is associated with epithelial 
mesenchymal transition while upregulation of miR-21 and 
miR-129 is associated with high grade tumors and poor 
prognosis, respectively [27, 102, 103].
Bladder cancer - current treatment 
Muscle invasion is a critical factor in the selection 
of the right therapeutic option for bladder cancer. In the 
case of non-muscle invasive bladder cancer, the standard 
clinical approach is transurethelial resection followed by 
administration of chemotherapeutic or immunotherapeutic 
agents [104]. For muscle-invasive bladder cancer, a 
more aggressive form, the standard of care is radical 
cystectomy [105]. In cases of disease relapse, occurring 
in approximately 30% of patients, combinatory 
chemotherapy regimens containing cisplatin are used. 
These include MVAC (Methrotrexate, Vinblastine, 
Achiamycin and Cisplatin) and GC (Gemcitabine and 
Cisplatin). Despite positive early responses to these 
therapeutic modalities, the median survival rate after 
treatment is only 12 months [104-106]. For advanced 
and metastatic bladder cancer, where surgery is not a 
valid approach, the only treatment option is palliative 
chemotherapy. This reflects the need for the development 
and implementation of new therapeutic agents [104].
Bladder cancer - pre-clinical data
Proteomic studies after exposure of bladder 
cancer cells to HDAC inhibitors reveals that HDAC 
activity influences many cellular pathways involved in 
carcinogenesis [107]. The treatment of bladder cancer 
cell lines with these agents resulted in cell growth 
suppression and induction of cell death [107]. Wang et al 
showed that the HDACi Vorinostat was able to induced 
cell growth inhibition in bladder cancer cells in part due 
to downregulation of survivin, an apoptosis inhibitory 
protein [108]. Importantly, Vorinostat had a synergistic 
effect with chemotherapeutic agents including Cisplatin, 
Mitomycin c, and Adriamycin. Combined therapy of using 
Vorinostat and Cisplatin prevented cancer progression in 
an animal model [108].
Positive responses were also obtained in bladder 
cancer cells after administration of the DNMTi Belinostat. 
A significant decrease in cell proliferation was observed 
in vitro, and in vivo with the use of a transgenic mouse 
model [109].
Epigenetic drugs can be used in combination 
with other agents to enhance their efficacy. Shang et al 
evaluated the DNMT inhibitor 5-Aza-2-deoxycytidine 
in combination with chemotherapeutic agents in bladder 
transitional cell carcinoma cell lines. The authors 
demonstrated that DAC enhances susceptibility to 
Cisplatin, a common agent used as neoadjuvant therapy 
for bladder cancer, in a synergistic way. Both agents 
induced cell cycle arrest at G2/M phase, with Cisplatin 
also inducing tumor cell apoptosis [110].
Rieger et al compared the efficacy and efficiency of 
Table 3: Clinical trials of epigenetic drugs in bladder cancer
Drug Combined Therapy Enzimatic Class Approval Stage Status Indication Results Reference/Clinical trial identification
Belinostat Carboplatin or paclitaxel HDAC inhibitor Phase 1/2
Phase 1 concluded, 
Phase 2 ongoing Bladder cancer
Four out of fifteen patients had 
complete or partial response 
 patients had progressive disease 
with median time to progression 
of 136 days
NCT00421889
Vorinostat - HDAC inhibitor Phase 2 Terminated for futility
Locally Recurrent or 
Metastatic Cancer of 
the Urothelium
No objective response was observed 
Median overall survival: 4,3 months 
Median progression free survival: 
1,1 months
NCT00363883
Mocetinostat - HDAC inhibitor Phase 2 Ongoing
Patients with 
advanced urothelial 
Carcinoma and 
inactivating 
alterations of 
acetyltransferase 
genes
Study completion date: December 
2017 NCT02236195
FdCyd Tetrahydrouridine DNMT inhibitor Phase 2 Ongoing 
Advanced cancer 
including bladder 
Cancer
Study completion date: May 2017 NCT00978250
OGX-427 Docetaxel
Antisense 
oligonucleotide that 
targets heat shock 
protein 27
Phase 2 Ongoing Advanced urothelial Carcinoma
Study completion date: February 
2017 NCT01780545
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siRNAS and antisense oligonucleotides against Bcl-xL in 
bladder cancer cell lines. Their effect in combined therapy 
with chemotherapeutic agents was also tested. Both agents 
enhanced tumor cell apoptosis when administrated with 
Cisplatin, however Bcl-xL knockout was more efficient 
with siRNAs than with antisense oligonucleotides [111]. 
Another study showed that simultaneous knockout of Bcl-
xL and survivin with siRNAs in bladder cancer cells led 
to greater sensitization of the cells to chemotherapeutic 
agents [112]. 
Bladder cancer - clinical data
Relative few studies of epigenetic therapies have 
been undertaken in bladder cancer. Only one of three 
clinical trials employing HDAC inhibitors showed a 
positive response; in this trial, four of fifteen patients 
treated with the HDACi Belinostat in combination with 
Carboplatin or Paclitaxel showed complete or partial 
response to treatment, while five patients presented 
disease progression with a median time to progression 
of 136 days (Table 3, NCT00421889). Further studies 
employing this HDACi in combination with other agents 
are essential to confirm its therapeutic potential [109]. 
The only study using the HDACi Vorinostat terminated 
due to lack of efficacy (Table 3, NCT00363883). Three 
other phase 2 clinical trials employing epigenetic drugs for 
bladder cancer treatment are currently ongoing (Table 3: 
NCT02236195, NCT00978250, NCT01780545).
CONCLUSIONS
Despite the obvious importance of epigenetics in the 
development of cancer, few epigenetic therapies have thus 
far reached advanced clinical testing. As the data above 
demonstrates, pre-clinical data has not translated into 
the hoped-for clinical responses. This is likely secondary 
to the nonspecific actions of epigenetic drugs and the 
consequent toxicities associated with their administration. 
Many of the epigenetic therapies being tested 
have global epigenetic effects on both cancerous and 
non-cancerous tissues. Moreover, some of them have 
additional non-epigenetic effects that limit their efficacy. 
HDAC enzymes, for instance, target non-histone proteins 
involved in oncologic pathways unrelated to epigenetic 
regulation [113]. It is important to consider that the 
observed therapeutic responses to HDACi treatment may 
thus be the result of the altered activity of these proteins 
and not to the reversal of specific epigenetic marks 
[113]. Similarly, demethylating agents are not specific 
to genes involved in carcinogenesis but result in global 
demethylation of the genome, an epigenetic signature 
associated with genomic instability that can lead to severe 
side effects [113]. 
Of all the clinical trials analyzed in this study, 16 
included evaluation of gene expression and/or DNA 
methylation as a secondary objective of the trial. We feel 
that analysis of gene expression and epigenetic patterns 
should be included in all clinical trials using epigenetic 
agents in order to assess the causal link between drug 
induced alterations and therapeutic responses. A better 
knowledge of the specific mechanism of action of these 
agents is essential to overcoming their clinical limitations 
and improving therapeutic success. 
Antisense oligonucleotides (ASOs) avoid some 
of the issues described above as as they are designed to 
be more target specific. Thus far, two separate studies of 
ASOs as monotherapy have shown no objective responses 
[71, 94], however when used in combination with other 
agents the results have been more promising [66, 93]. 
However, ASOs also have their limitations secondary to 
toxicity and delivery efficiency [67, 69].
Currently, cancer treatment is determined largely 
according to cancer stage, even though patients with 
similar stage cancers may respond differently to the same 
type of therapy. The promise of “personalized medicine” 
is the idea that tailoring treatment to an individual 
patient will optimize efficacy while minimizing toxicity. 
Personalization should be an ongoing goal for all cancer 
therapy development, including epigenetic therapies. 
Biomarker development should thus be a central goal in 
the development of epigenetic therapies, both so that the 
correct patient receives the correct therapy, and to ensure 
that therapies that have value in a subset of patients 
are not passed over because of lack of efficacy in other 
patients. Epigenetic therapies are still in their infancy as 
a therapeutic class and pre-clinical promise has not yet 
translated into clinical efficacy. However, the development 
of target-specific agents, and the careful combination of 
epigenetic therapies with traditional modalities should 
enable them to achieve clinical success in the near future. 
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